ABOUT THE PRODUCT
Pedmark is a novel compound developed by Fennec Pharmaceuticals to reduce the incidence of hearing loss in children undergoing chemotherapy. It is designed to mitigate the ototoxic effects of cisplatin-based chemotherapy regimens.
Information is owner-confirmed
Last updated 5 months ago
Price range